LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Kura Oncology Inc

Chiusa

SettoreSettore sanitario

5.79 -4.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.74

Massimo

6.09

Metriche Chiave

By Trading Economics

Entrata

-38M

-57M

Vendite

-40M

14M

EPS

-0.66

Margine di Profitto

-407.067

Dipendenti

192

EBITDA

-48M

-65M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+271.1% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

56M

582M

Apertura precedente

10.4

Chiusura precedente

5.79

Notizie sul Sentiment di mercato

By Acuity

34%

66%

104 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Kura Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2025, 22:34 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mag 2025, 23:48 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mag 2025, 23:46 UTC

Discorsi di Mercato

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mag 2025, 23:34 UTC

Discorsi di Mercato

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mag 2025, 23:21 UTC

Discorsi di Mercato

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mag 2025, 22:54 UTC

Discorsi di Mercato

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mag 2025, 22:43 UTC

Utili

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mag 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mag 2025, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mag 2025, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Australia Retail Electricity Business to AGL

12 mag 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mag 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mag 2025, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mag 2025, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mag 2025, 21:15 UTC

Notizie principali

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q Rev $2.65B >CSU.T

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q Net $115M >CSU.T

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q EPS $5.44 >CSU.T

12 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

12 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

12 mag 2025, 20:44 UTC

Notizie principali

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mag 2025, 20:31 UTC

Notizie principali

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mag 2025, 20:24 UTC

Utili

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mag 2025, 20:24 UTC

Utili

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mag 2025, 20:24 UTC

Notizie principali

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mag 2025, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mag 2025, 20:15 UTC

Utili

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mag 2025, 20:10 UTC

Utili

Blink Charging 1Q Rev $20.8M >BLNK

Confronto tra pari

Modifica del prezzo

Kura Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

271.1% in crescita

Previsioni per 12 mesi

Media 22.6 USD  271.1%

Alto 40 USD

Basso 10 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Kura Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

10

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.575 / 6.6Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

104 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.